Stock Screener App

Gratuito -

Installare

90.14

1.36% 1.21

Blueprint Medicines Corp (BPMC)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché BPMC Giù? Forum Previsione

Blueprint Medicines Corp Borsa (BPMC) Ultime notizie

Blueprint Medicines director Jeffrey Albers sells $1.35 million in stock - Investing.com India

Blueprint Medicines COO Christina Rossi sells $218,098 in shares By Investing.com - Investing.com Australia

Blueprint Medicines COO Christina Rossi sells $218,098 in shares - Investing.com

Insider Sell: Christina Rossi Sells Shares of Blueprint Medicines Corp (BPMC) - GuruFocus.com

Blueprint Medicines Co. (NASDAQ:BPMC) Director Jeffrey W. Albers Sells 15,000 Shares - MarketBeat

Insider Selling: Blueprint Medicines Co. (NASDAQ:BPMC) COO Sells 2,274 Shares of Stock - MarketBeat

Blueprint Medicines (NASDAQ:BPMC) Shares Down 3.6%What's Next? - MarketBeat

Blueprint Medicines Corporation Seeks Validation of 2024 Stockholder Actions Through Section 205 Action - Defense World

Blueprint Medicines' SWOT analysis: stock's potential in precision oncology - Investing.com

Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference – Company Announcement - Financial Times

Geode Capital Management LLC Raises Stock Position in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat

Blueprint Medicines Co. (NASDAQ:BPMC) Insider Sells $169,639.94 in Stock - MarketBeat

Blueprint Medicines officer sells shares worth $169,635 - Investing.com

Blueprint Medicines officer sells shares worth $169,635 By Investing.com - Investing.com UK

Blueprint Medicines Co. (NASDAQ:BPMC) Shares Sold by Barclays PLC - MarketBeat

Blueprint Medicines Co. (NASDAQ:BPMC) Sees Large Growth in Short Interest - MarketBeat

Blueprint Medicines' SWOT analysis: stock outlook amid Ayvakit success - Investing.com

Blueprint Medicines Co. (NASDAQ:BPMC) Shares Bought by State Street Corp - MarketBeat

Blueprint Medicines Co. (NASDAQ:BPMC) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Zimmer Partners LP Makes New Investment in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat

Blueprint Medicines Co. (NASDAQ:BPMC) Shares Sold by Castleark Management LLC - MarketBeat

Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting - Quantisnow

Holocene Advisors LP Sells 926,550 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat

Blueprint Medicines Co. (NASDAQ:BPMC) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat

Blueprint Medicines (FRA:2L9) Profitability Rank : 3 (As of Sep. 2024) - GuruFocus.com

Jacobs Levy Equity Management Inc. Buys 306,079 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat

Blueprint Medicines CEO Kate Haviland sells $227,304 in shares By Investing.com - Investing.com Australia

Blueprint Medicines CEO Kate Haviland sells $227,304 in shares - Investing.com

Erste Asset Management GmbH Purchases New Holdings in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat

Blueprint Medicines Co. (NASDAQ:BPMC) Short Interest Down 5.3% in November - MarketBeat

The Manufacturers Life Insurance Company Has $13.88 Million Stake in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat

Exploring Three High Growth Tech Stocks in the United States - Simply Wall St

Blueprint Medicines Co. (NASDAQ:BPMC) Shares Bought by Edgestream Partners L.P. - MarketBeat

Fred Alger Management LLC Sells 15,478 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat

Blueprint Medicines Co. (NASDAQ:BPMC) Shares Acquired by Charles Schwab Investment Management Inc. - MarketBeat

Fmr LLC Sells 316,913 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat

Connor Clark & Lunn Investment Management Ltd. Buys Shares of 5,132 Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World

Eventide Asset Management LLC Grows Stock Holdings in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat

Blueprint Medicines (BPMC) Up 8.7% Since Last Earnings Report: Can It Continue? - Yahoo Finance

Alkeon Capital Management LLC Has $66.50 Million Stock Position in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat

Blueprint Medicines Co. (NASDAQ:BPMC) Shares Purchased by Citigroup Inc. - MarketBeat

Blueprint Medicines Co. (NASDAQ:BPMC) Shares Purchased by Ally Bridge Group NY LLC - MarketBeat

Intech Investment Management LLC Takes Position in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat

Massachusetts Financial Services Co. MA Has $23.33 Million Position in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat

Pitcairn Co. Has $954,000 Stock Holdings in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat

BNP PARIBAS ASSET MANAGEMENT Holding S.A. Acquires New Position in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat

Blueprint Medicines (FRA:2L9) EPS without NRI : €-4.43 (TTM As of Sep. 2024) - GuruFocus.com

Blueprint Medicines (FRA:2L9) Revenue per Share : €6.33 (TTM As of Sep. 2024) - GuruFocus.com

Blueprint Medicines (FRA:2L9) Operating Cash Flow per Share : €-3.56 (TTM As of Sep. 2024) - GuruFocus.com

Algert Global LLC Purchases 26,696 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat

Blueprint Medicines Co. (NASDAQ:BPMC) Shares Sold by Eagle Asset Management Inc. - MarketBeat

Blueprint Medicines director Coats sells $1.87 million in stock - Investing.com India

Principal Financial Group Inc. Sells 47,153 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat

Blueprint Medicines director Coats sells $1.87 million in stock By Investing.com - Investing.com Canada

What is Zacks Research's Forecast for BPMC FY2024 Earnings? - MarketBeat

Segall Bryant & Hamill LLC Buys 14,668 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat

Blueprint Medicines (LTS:0HOJ) Enterprise Value : $5,746.9 Mil (As of Nov. 20, 2024) - GuruFocus.com

Blueprint Medicines initiated with an Overweight at JPMorgan - MSN

Blueprint Medicines Co. (NASDAQ:BPMC) Stock Holdings Cut by Victory Capital Management Inc. - MarketBeat

JMP Securities Reaffirms Market Outperform Rating for Blueprint Medicines (NASDAQ:BPMC) - MarketBeat

SMMT

$17.87

2.88%

INCY

$68.84

2.65%

MRNA

$39.39

0.43%

UTHR

$359.58

0.16%

BGNE

$176.50

1.02%

BNTX

$113.08

1.56%

Apri su Yahoo | Apri su Google | Aperto in Finviz | Apri in MarketWatch | Aperto a EDGAR | Aperto su Reuters